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Current Clinical Issues: Deposition 
of Gadolinium Chelates
Takahito Nakajima and Oyunbold Lamid-Ochir
Abstract
Clinically available gadolinium chelate-based contrast agents (GBCAs) are 
divided into two groups by chelate types: linear GBCAs and macrocyclic GBCAs. 
The characteristic features of GBCAs are introduced in this chapter. Currently, there 
are two clinical issues related to the administration of GBCAs: nephrogenic systemic 
fibrosis (NSF) and brain deposition of gadolinium. NSF occurs in patients with 
chronic renal failure who had magnetic resonance imaging (MRI) examinations with 
GBCA injections. Frequent administrations would induce NSF, and GBCA stability 
would be discussed in this chapter. Linear GBCAs are more likely to be deposited in 
brain tissues than macrocyclic GBCAs. We present the trend of GBCA deposition or 
retention with our published research studies with our previous researches. We have 
investigated the effect of GBCAs deposited in the brain for infants.
Keywords: gadolinium-based contrast agent, nephrogenic systemic fibrosis, 
linear chelates, macrocyclic chelates, gadolinium brain deposition
1. Introduction
1.1 Development history
Magnetic resonance imaging (MRI) is a powerful cross-sectional diagnostic 
imaging modality. Its technical principle developed by Bloch and Purcell was 
advanced for clinical application since 1973 by Lauterbur and Mansfield [1]. MRI 
allows a generation of noninvasive images and a determination of detailed internal 
morphology and function of organs and tissues, rendering it particularly useful for 
detection and characterization of diseased soft tissue including solid tumors. MRI 
has many advantages such as the absence of ionizing radiation exposure and provides 
three-dimensional images with high spatial resolution and contrast. The quality of 
MR images, including spatial resolution, signal-to-noise ratio, and contrast-to-noise 
ratio (CNR), has been markedly improved in the past decades. In addition, the use 
of contrast agents (CAs) has been playing a crucial role in improving the detection 
of tumor lesions, especially brain tumors, due to a rupture of blood-brain barrier by 
enhancing the image contrast between normal and abnormal tissues [2, 3].
1.2 Contrast mechanism
CAs in the field of MRI alter the longitudinal (T1) and transverse (T2) relax-
ation rates of the surrounding water protons, therefore enhancing the image 
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contrast in tissue of interest [4]. MRI CAs generally behave as positive CAs on 
T1-weighted image (T1WI) or negative CAs on T2WI based on their relaxation 
mechanisms. Gadolinium-based contrast agents (GBCAs) are commonly used as 
T1 contrast agents that have the ability to decrease T1 relaxation times of protons 
and work as a positive image contrast on T1WI. GBCAs have been commercially 
introduced since 1988 and have been globally used for more than 25 years in more 
than 100 million patients, and over 10 million contrast-enhanced MRI scans were 
annually performed [5]. These agents distribute into plasma, interstitial spaces, and 
extracellular spaces immediately after intravenous injection. Since most GBCAs 
are employed as extracellular agents, dynamic study of MRI has been performed to 
detect hypervascular tumors, such as hepatocellular carcinoma. The extracellular 
distribution of GBCAs is most effective in detection and diagnosis of disrupted 
blood-brain barrier in the central nervous system such as multiple sclerosis and 
brain tumor [6, 7].
1.3 Relaxivity
The relaxation of solvent nuclei around paramagnetic center has been described 
by Solomon, Bloembergen, and others [8]. Every material has proper T1 and T2 
relaxation rates (1/T1, 1/T2) of water protons, and the difference of relaxivities 
produces the contrasts among tissues. The use of BCAs can increase both T1 and T2 
relaxation rates (1/T1, 1/T2) of water protons. The observed water proton relax-
ation rates contribute to the contrast of the relaxation rates (1/T1, 1/T2) without 
GBCAs, and the increased relaxation rates (1/T1, 1/T2) are promoted using GBCAs. 
The increased relaxation rates of water protons are linearly related to the concentra-
tion of GBCAs within the range of clinically relevant concentrations. The relaxivity 
is defined as a concentration-dependent increase in relaxation rate of water protons 
by GBCAs in the units of mM−1 s−1 [2].
  (1 / T1, 2) obs =  (1 / T1, 2) d + r1, 2  [Gd] (1)
Protein-binding GBCAs, Gd-BOPTA (MultiHance), Gd-EOB-DTPA (Eovist), 
and MS-325 (Ablaber), have increased relaxivity in plasma because of their non-
covalent binding to albumin which slows down the molecular rotation [2, 8]. In 
particular, MS-325 has an r1 relaxivity as high as 28 ± 1 mM−1 s−1 when measured at 
0.47 T and 37°C in plasma [9].
1.4 Safety
Safety of GBCAs for clinical applications is another critical issue because of 
the reported harmful effects of Gd3+ in patients. Gd3+ ions are highly toxic in ionic 
form due to interference with calcium channel and protein-binding sites. This is 
because the ionic radius of Gd3+ ions is almost equal to that of Ca2+ and Gd3+ can 
compete with Ca2+ and cause toxic side effects for the biological system. Free Gd3+ 
ions accumulate in the spleen, liver, bone, and kidney, and LD50 of free Gd3+ ion 
is 0.2 mmol kg−1 in mice. To prevent the toxicity of Gd3+ ions, chelate ligands are 
employed to reduce free Gd3+ ions. Harmful Gd3+ ions may still be released from 
some type of chelates. The mechanism of release of free Gd3+ from chelated CAs has 
been investigated. One of the hypotheses is transmetallation with other metal ions, 
including Zn2+, Ca2+, and Cu2+ in the serum of human body. Another hypothesis is 
the protonation of the ligands at low pH. These factors would cause chelate dissoci-
ation in vivo [10]. Therefore, gadolinium chelate-based MRI CAs emerged for their 
good safety profiles and the stability for high thermodynamic and kinetic stability.
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The GBCAs are excreted from the kidney within hours after intravenous 
administration [11]. GBCAs are ultimately eliminated through the renal route with 
half-lives of 1–2 h and excreted intact in urine (more than 95% of the injected dose 
in 24 h). The dose of these small molecular GBCAs in clinical use is usually 100 
times lower than their LD50. GBCAs used to be used as a contrast agent of MRI even 
for patients with chronic kidney disease (CKD). However, in 2006, nephrogenic 
systemic fibrosis (NSF) was reported by Grobner. Many papers reported that CKD 
might be the main factor of NSF [12, 13]. These days, GBCAs are not used for 
patients with CDK.
2. Chelate types of gadolinium-based contrast agent
GBCAs are categorized mainly into two groups: linear and macrocyclic GBCAs. 
In general, macrocyclic GBCAs are more stable than linear GBCAs due to higher 
thermodynamic and kinetic stability (Tables 1–4) [14, 15]. In clinical use, gado-
pentetate dimeglumine, Gd-DTPA (Magnevist); gadoterate, Gd-DOTA (Dotarem); 
gadoteridol, Gd-HP-DO3A (ProHance); and gadodiamide, Gd-DTPA-BMA 
(Omniscan) have similar r1 relaxivity in the range of 3.5–3.8 mM−1 s−1 (20 MHz and 
37°C) (Tables 1–4).
2.1 Linear chelates
Gadolinium-DTPA: Gadopentetate dimeglumine, Gd-DTPA (Magnevist), is one 
of the linear-type chelating agents. Gd3+ ions are covered by the polydentate ligand 
like a claw (Figure 1). The toxicity of Gd-DTPA is more than tenfold lower than the 
toxicity of Gd3+ ion and DTPA as a ligand. Its safety profile is very well established 
with low incidence of adverse effects. The risk of adverse reactions is low when then 
agent is administrated intravenously even up to doses of 0.03 mol/kg.
Commercial name Chemical name Structure Chelate type
Magnevist Gadopentetate dimeglumine Gd-DTPA Linear
Omniscan Gadodiamide Gd-DTPA-BMA Linear
Dotarem Gadoterate meglumine Gd-DOTA Macrocyclic
ProHance Gadoteridol Gd-HP-DO3A Macrocyclic
Gadovist Gadobutrol Gd-DO3A-butrol Macrocyclic
Table 1. 
Representative clinical gadolinium-based contrast agents (GBCAs).
GBCAs LD50 (mmol/kg) References
Gd-DTPA 8 [16]
Gd-DTPA-BMA 25 [18]
Gd-DOTA 18 [17]
Gd-HP-DO3A <15 [19]
Gd-DO3A-butrol 25 [18]
GBCA, Gadolinium-based contrast agent; LD50, median lethal dose.
Table 2. 
Acute intravenous toxicity in rats [14].
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Gadolinium-DTPA-diamides: Two extracellular contrast agents that contain 
neutral gadolinium chelates have entered the market: gadodiamide, Gd-DTPA-
BMA (Omniscan) (Figure 2), and gadoversetamide (Optimark) (Figure 3). 
Both ligands are amides of DTPA and are obtained by treating the dianhydride 
of DTPA, corresponding to amine. These gadolinium complexes are freely 
soluble in water. As expected, the osmolality of the 0.5 molar solution of gado-
diamide is lower (0.79 osmol/kg water) than that of the 0.5 molar solution of 
Gd-DTPA.
GBCAs Concentration 
(mmol/l)
Osmolality 
(osmol/kgH2O)
Viscosity References
Gd-DTPA 0.5 1.96 2.9 [20]
Gd-DTPA-BMA 0.5 0.79 1.4 [18, 20]
1.0 1.90 3.9 [19]
Gd-DOTA 0.5 1.35 2.0 [19]
1.0 4.02 11.3 [19]
Gd-HP-DO3A 0.5 0.63 1.3 [19]
1.0 1.91 3.9 [19]
Gd-DO3A-butrol 0.5 0.57 1.4 [18]
1.0 1.39 3.7 [20]
GBCA: Gadolinium-based contrast agent.
Table 3. 
Physiochemical properties of formulations of gadolinium complexes.
GBCAS log K (therm) 1/T1 relaxivity (1/mmol−1)s−1 References
Gd-DTPA 22.2 3.8 [18]
Gd-DTPA-BMA 16.9 3.9 [21]
Gd-DOTA 24.7 3.5 [21]
Gd-HP-DO3A 23.8 3.7 [21]
Gd-DO3A-butrol 21.8 3.6 [18]
Table 4. 
Thermodynamic stability constants and relaxivities.
Figure 1. 
Gadopentetate dimeglumine, Gd-DTPA (Magnevist).
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2.2 Macrocyclic chelates
Gadolinium-DOTA: The second generation of GBCAs contains the derivatives 
of the macrocyclic tetramine, 1.4.7.10-tetraazacyclododecane (cyclen). Gadoterate, 
Gd-DOTA (Dotarem, Figure 4), was the first macrocyclic gadolinium complex that 
was released in the market. In the macrocyclic structure, the metal-binding site 
within the ligand is more encapsulated, and the entropy is decreased upon metal 
incorporation. According to previous results, the stability of macrocyclic metal 
chelates is higher than that of linear complexes. The macrocyclic complexes exhibit 
a higher kinetic stability [10].
Figure 2. 
Gadodiamide, Gd-DTPA-BMA (Omniscan).
Figure 3. 
Gadoversetamide (Optimark).
Figure 4. 
Gadoterate, Gd-DOTA (Dotarem).
Rare Earth Elements and Their Minerals
6
Gadolinium-DO3A: The nonionic open-chain metal chelates and neutral 
macrocyclic gadolinium chelates have been synthesized. Two of them such as 
gadobutrol (Gadovist) (Figure 5) and gadoteridol (ProHance) (Figure 6) have 
been launched as extracellular MRI contrast agents. Both agents are derivatives of 
1,4,7-tricarboxymethyl-1,4,7,10-tetraazacyclododecane (DO3A).
Thermodynamic stability constants and relaxivities in water at 20 MHZ and 
40°C of commercially available gadolinium chelates.
3. Nephrogenic systemic fibrosis (NSF)
Nephrogenic systemic fibrosis (NSF) is a multi-systemic fibrosing disease that 
has been characterized by thickening and tightening of the skin and subcutane-
ous tissues. NSF also includes fibrosis of the skeletal muscle, lung, liver, testis, or 
myocardium with possible fatal outcomes.
First described in 1997, NSF was initially known as nephrogenic fibrosing 
dermopathy because of its classic presentation of symmetric, brawny, or erythema-
tous indurated cutaneous plaques that develop in the setting of renal insufficiency 
[13, 22, 23]. Grobner’s published case reports have found an association of NSF with 
GBCAs exposure when a meticulous chart review was performed. Currently, over 
250 documents reporting NSF cases have been registered by Shawn Cowper of Yale 
University, which have linked 85% of its cases to gadodiamide (Omniscan) [23–25].
Figure 5. 
Gadobutrol (Gadovist).
Figure 6. 
Gadoteridol (ProHance).
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3.1 Pathogenesis of NSF
The exact pathogenesis of NSF is still unclear. However, there are some evi-
dences suggesting that it likely involves the migration of CD34 and procollagen-1 
positive, circulating fibrocytes from the blood to the engaged tissue as proposed 
by Cowper. These fibrocytes likely activate a fibrotic response through cytokine 
production and T-cell activation. Several reports have shown increased expression 
of transforming growth factor β1 and CD68-factor XIIIa within the affected skin 
and skeletal muscle which are also essential markers associated with wound healing 
and fibrosis [26, 27].
In addition, evidence of in vivo transmetallation has been provided by a preclin-
ical trial in which rats exposed to repeated high-dose GBCAs injection developed an 
NSF-like skin lesion consisting of epidermal ulceration, acanthosis, dermal fibrosis, 
and CD34 fibrocytic infiltration with high concentrations of gadolinium in the skin. 
These findings were more severe with gadodiamide (Omniscan) than gadopentetate 
(Magnevist) [28]. The differences in conditional thermodynamic stability constants 
and stimulatory response of gadodiamide on fibroblasts may explain the higher 
incidence of NSF with gadodiamide (Omniscan). The medical literature report of 
NSF and this additional evidence seem to indicate a stratified risk within the class 
of GBCAs. The transmetallation of the gadolinium chelate would occur because of 
exchange of Gd3+ ions for endogenous metals (such as Zn, Cu, and Ca), and then 
free Gd3+ ions are released from the chelate. Patients with severe or end-stage renal 
disease are more likely to undergo in vivo transmetallation because of markedly 
prolonged clearance of GBCA. This theory has been substantiated by detection 
of gadolinium within tissue months after GBCA exposure. And transmetallation 
of Gd-DTPA with endogenous Fe(II)/Fe(III) is possible in human blood plasma. 
Telgmann concluded that transmetallation may be a trigger of NSF if free Fe(III) 
ions were accessible during a prolonged pathway of Gd complexes with linear 
ligands through the patient’s body [29].
3.1.1 Clinical features of NSF
1. Onset: A few days to 20 years later. The early clinical symptoms of NSF include 
pain, pruritus, swelling, erythema (usually starts in the legs), transient alope-
cia, as well as gastrointestinal symptoms of nausea, vomiting, diarrhea, and 
abdominal pain.
2. Lately, main symptoms emerge such as nodules developing on the skin; thick-
ened skin and subcutaneous tissues, “woody” texture and brawny plaques; 
joint regulation; and severe pain. Additionally, the fibrosis process involves 
the internal organs, e.g., muscle, diaphragm, heart, liver, and lungs. All these 
processes could lead to joint contractures, cachexia, and death, in a proportion 
of patients [12, 24].
3.2 Risk patients
High-risk patients have a history of CKD 4 and 5 (glomerular filtration rate 
(GFR) < 30 ml/min), dialysis, and with reduced renal function who have had or are 
awaiting liver transplantation. The lower risk includes patients with CKD 3 (GFR 
30–59 ml/min) and children under 1 year, because of their immature renal function 
[22]. Younger children and elderly persons are not affected by NSF because their 
immune system is immature [23]. Although the pathogenesis is not revealed, the 
immune system might have a key role in inducing NSF.
Rare Earth Elements and Their Minerals
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No cases of NSF have been reported in patients with GFR greater than 60 ml/
min. The role of various possible cofactors in the pathogenesis of NSF is not proven.
Pregnant patients. In the absence of specific information, it seems wise to 
manage pregnant patients, regardless of their renal function, in the same way as 
children aged under 1 year to protect the fetus.
In the use of GBCAs, serum creatinine should be measured before gadolinium 
contrast media administration for all patients.
3.2.1 Key points of risk patients
1. Approximately 40–50% of MRI patients receive Gd-CM.
2. The percentage of patients with CKD 3, 4, and 5 varies in different institutions.
3. Serum creatinine and estimated GFR (eGFR) are not always very accurate 
indicators of true GFR. In particular, acute renal failure may not be indicated 
by a single eGFR value.
4. Measurement of serum creatinine/eGFR before Gd-CM is mandatory before 
Gd-CM which have been associated with subsequent development of NSF.
5. Measurement of serum creatinine/eGFR is not necessary in all patients receiv-
ing Gd-CM.
3.3 Use of gadolinium-based contrast agents
Three GBCAs (gadodiamide, gadoversetamide, and gadopentetic acid) are 
currently FDA-contraindicated in patients with GFR <30 mL/min/1.73 m2. The 
American College of Radiology (ACR) recommends screening GFR of any patients 
with known or suspected renal impairment and advises against the use of any 
GBCA in patients with GFR <30 mL/min/1.73 m2, suffering acute kidney injury, or 
requiring dialysis [30].
3.3.1 General points
1. The risk of inducing NSF must always be weighed against the risk of denying pa-
tients gadolinium-enhanced scans which are essential for patient management.
2. In patients with impaired renal function, liver transplant patients, and neo-
nates, the benefits and risks of gadolinium enhancement should be considered 
particularly carefully.
3. In patients with CKD 4 and 5 (<30 ml/min):
• Always use the smallest possible amount of the contrast agent to achieve an 
adequate diagnostic examination.
• Never use more than 0.3 mmol/kg of any Gd-CM.
• Never use gadolinium as a contrast agent for radiography, computed tomog-
raphy, or angiography as a method of avoiding nephropathy associated with 
iodinated contrast media.
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3.4 How to choose gadolinium-based contrast agents?
There are differences in the incidence of NSF with different GBCAs, which 
appear to be related to differences in physicochemical properties and stability. 
Since macrocyclic GBCAs are preorganized rigid rings of almost optimal size to 
cage the gadolinium ions which have high stability compared with linear GBCAs, 
macrocyclic GBCAs are recommended to inject to patients with mild to moderate 
CKD. According to the current knowledge about the properties of the different 
agents and the incidence of NSF, macrocyclic GBCAs should be used for high-risk 
patients [31].
4. Gadolinium deposition in human body
4.1 Retention of gadolinium
The retention of gadolinium in the human body has become an issue of consid-
erable global interest these days. Gadolinium retention was observed in the bone 
and in the brain in patients without renal failure [32]. The pharmacokinetics of dif-
ferent gadolinium chelates have been studied in healthy patients and in those with 
varying degrees of renal impairment. The main pathway of elimination is glomeru-
lar filtration [33]. The mean elimination half-life of GBCAs is 1.3–1.5 h. In patients 
with severe renal insufficiency, the half-life increases to 34.3 h [7]. Currently, it is 
known that gadolinium is retained in body tissues, regardless of levels of renal func-
tion or even GBCA stability [22]. Higher concentrations appear to occur in patients 
with renal impairment or after exposure to less stable GBCAs [34].
Our recent study found that a long-term Gd retention for GBCAs was almost 
unaffected by renal function [35, 36]. This finding suggested that the chemical 
structures of retained Gd may not be homogeneous and some Gd could be slowly 
eliminated after being initially retained in the tissues. Moreover, Gd retention was 
greater when linear GBCA was administered, than macrocyclic GBCA. However, 
the presence of the blood–brain barrier (BBB) likely plays a role in the mechanism 
of Gd retention in the brain. The mechanism of retention and the shapes of GBCAs 
have not been adequately revealed yet. Although injection doses should be mini-
mized for all patients, some reports suggest that injection times would be more 
important than injection doses [27, 37–39].
Gadolinium has some isotopes such as 154Gd, 155Gd, 156Gd, 157Gd, 158Gd, 
and 160Gd as stable isotopes and 152Gd as a radioisotope. Biodistribution study 
of various GBCAs was performed in 1995 using a radioisotope of 153Gd. 153Gd 
was labeled to gadopentetate (Magnevist), gadoteridol (ProHance), gadoterate 
(Dotarem), and gadodiamide (Omniscan) [40]. All GBCAs were excreted from ani-
mal body within 60 min, and GBCAs in blood pool were completely disappeared. 
The liver, kidney, femur bone, and gastrointestinal tract still retain GBCAs until 
14 days. These days the measurements of gadolinium are performed by inductively 
coupled plasma mass spectroscopy (ICP-MS). In our researches, either 158Gd or 
160Gd is measured by ICP-MS. The technology of imaging mass would contribute 
to reveal the distribution of gadolinium in vivo [41, 42].
Gregory WW reported the gadolinium concentration remaining in human 
bone tissue after administration of 0.1 mmol/kg of two types of GBCA, Omniscan 
(Gd-DTPA-BMA) or ProHance (Gd-HP-DO3A), to patients undergoing hip 
replacement surgery. Tissue retention in bone for Omniscan (Gd-DTPA-BMA) 
was significantly higher than those for ProHance (Gd-HP-DO3A) measured 
by ICP-MS. Omniscan (Gd-DTPA-BMA) left approximately four times more 
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gadolinium behind in bone than did ProHance (Gd-HP-DO3A). These results would 
indicate two important issues: (1) chelate stability and (2) affinity of GBCA to the 
bone. Linear GBCAs like Omniscan (Gd-DTPA-BMA) would release more Gd3+ ions 
than macrocyclic GBCAs like ProHance (Gd-HP-DO3A). Since the bone is a known 
natural repository for unchelated Gd3+ ions, free Gd3+ ions released from Omniscan 
(Gd-DTPA-BMA) would retain bone. Another reason to deposit gadolinium to bone 
would be the affinity of GBCAs to bone. Hydroxyapatite structure is similar to the 
structure of DTPA. It might be one of causes for linear GBCAs, especially Gd-DTPA 
or Gd-DTPA-BMA to retain bone.
4.2 Gadolinium deposition in the brain (Kanda reports)
In 2014, Kanda et al. reported unusual brain MRI findings in patients with a his-
tory of various GBCAs administration [43] (Figures 7 and 8). High signal intensity 
of the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images 
was seen in patients with frequent administrations of GBCAs. Signal intensities on 
T1WI showed a positive correlation with the number of previous GBCA adminis-
trations, even in patients with normal renal function. Furthermore, the positive 
correlation with numbers of GBCA administrations and signal intensities on T1WI 
was noted only for patients with linear GBCA administrations, while no correla-
tions were seen in patients with macrocyclic GBCA administrations [15, 44, 45]. 
Several researchers also reported a presence of hyperintensity in the dentate nucleus 
that corresponded with the number of past linear GBCAs administrations [46, 47]. 
Similar findings were reported in pediatric patients [30, 43].
The cause of high signals in the globus pallidus continues to be a hot topic in this 
field. Cadaver studies with quantitative analyses using mass spectroscopy revealed 
high signal intensities of the globus pallidus in patients with frequent GBCA 
administrations would be based on gadolinium. Although high signal intensities 
in the globus pallidus have been also observed in patients who have a history of 
liver failure, Wilson disease, Osler-Weber-Rendu disease, manganese toxicity, 
calcification, hemodialysis, total parenteral nutrition, and neurofibromatosis type 
1, various kinds of metal ions would be deposited in the globus pallidus. However, 
the forms of gadolinium deposition have not been known whether chelate type, 
Figure 7. 
Unenhanced T1-weighted MR image. Signal increase on unenhanced T1-weighted MR image in the basal 
ganglia, which is indicated by arrowheads.
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gadolinium ions, and phosphate or other complexes. In serum or blood, gadolinium 
ion released from GBCAs tends to bind to phosphate quickly and to make a form of 
phosphate complex with gadolinium. Since phosphate complex has no signals on 
MRI, phosphate complex would not be a cause of high signals in the globus pallidus. 
In our speculation, macromolecules of gadolinium bound to protein would be one 
of the candidates for deposition in the brain. The reason for our speculation is that 
gadolinium ions bound to macromolecules show much brighter signals on T1WI 
than those of small molecules, which is based on the model known as the Solomon-
Bloembergen-Morgan formula. Since the macromolecule rotates slowly compared 
with small molecules, the contact time with gadolinium and water proton can be 
prolonged, and the T1 shortening effect of gadolinium can be increased. The high 
signals in the globus pallidus would be derived from the role of macromolecules 
bound to gadolinium.
4.3 Effect in the central nervous system (CNS)
Gd3+ affects the development of infant CNS: In our previous study, we reported 
that Gd was transferred to pups and was retained in their brain during postnatal 
period. The perinatal exposure to GBCAs induced behavioral changes in mice; 
gadodiamide (Omniscan) had a more severe effect than gadoterate meglumine 
(Dotarem). All pups were separated from mothers for weaning on P21, and the 
total Gd in the brain of mothers and pups were measured on P28. Higher dose of Gd 
retention was found in mothers and pups in the linear-type group. Perinatal admin-
istration of GBCAs caused anxiety-like behaviors, disrupted motor coordination, 
impaired memory function, stimulated tactile sensitivity, and decreased muscle 
strength, especially in the gadodiamide-treated group [48]. In linear GBCA group, 
the total Gd retention in the brain of the mothers and the pups was higher than in 
the macrocyclic group. Both GBCAs were intravenously injected with 2 mmol/kg 
into the mothers from E15 to E19, which is the critical period for the development 
of neuronal circuits in fetus. According to the results of this study, we investigated 
Gd retention in various organs in both the mother and pup mice models [49]. Gd 
retentions in mother mice were consistently higher after gadodiamide (Omniscan) 
administration than gadoterate meglumine (Dotarem). Moreover, significantly 
Figure 8. 
Unenhanced T1-weighted MR image. Signal increase on unenhanced T1-weighted MR image in the dentate 
nucleus of the cerebellum, which is indicated by arrowheads.
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higher Gd retention was observed in the organs of pups after whose mothers were 
administered gadodiamide (Omniscan) than gadoterate meglumine (Dotarem) 
(Figure 9). The results indicated that the linear GBCA affected not only the brain 
but also other maternal organs, such as the bone, spleen, and liver. Though the 
effects of maternal GBCA administration have not been reported in humans, our 
studies would warn the potential risk of using GBCAs in pregnant women.
4.4 Glymphatic system
The glymphatic system is discovered as a brain waste system to transport low 
molecular weight materials from the cerebrospinal fluid (CSF) to the interstitial 
fluid (ISF). The glymphatic system may also transport GBCAs to the brain. Ilif 
et al. examined GBCA deposition in the brain with rat by MRI [50]. When GBCA 
was injected into the rat subarachnoid space, it moved along the basilar artery into 
the brain parenchyma. In addition, Eide et al. evaluated patients who had GBCA 
administrations in the subarachnoid space with MRI [51]. Four hours after GBCA 
administration in the subarachnoid space, both the cortical and white matter of the 
brain showed high signal intensities, and the gadolinium entrance to the human 
brain through the glymphatic system was speculated. Naganawa et al. reported 
that on post contrast FLAIR image, the subarachnoid space and perivascular space 
showed increased signal intensities and GBCA transfer to the subarachnoid space 
and perivascular space on brain MRI of 27 subjects who had administrated GBCA 
before 4 h [52].
These results demonstrated that even in patients with normal renal function, 
intravenously administered GBCA can be transported through the glymphatic sys-
tem and reach the brain. However, the association between the hyperintensity in the 
globus pallidus and dentate nucleus and the GBCA that is transported through the 
glymphatic system is still unclear. The glymphatic system transports all low molecu-
lar weight materials passively, and both the linear type of GBCA and macrocyclic 
GBCA are transported in the same way. However, the signal intensity of the dentate 
Figure 9. 
Gadolinium depositions in organs of mother mice and their pups. The gadolinium concentrations in the organs 
of mice with the administration of linear GBCA (Gd-DTPA-BMA) were higher than those of macrocyclic 
GBCA (Gd-DOTA) [49].
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nucleus varies according to the type of administered GBCA. In addition, the distri-
bution of gadolinium cannot be explained by passive transportation. The accumula-
tion of GBCA in the brain is probably due to some extent to the glymphatic system, 
but any association between the glymphatic system and signal hyperintensity of the 
dentate nucleus remains obscure.
5. Conclusion
We discussed two types of GBCAs: linear chelates and macrocyclic chelates. The 
macrocyclic GBCAs are more stable than the linear types because free Gd ions do 
not get released from the macrocyclic chelates easily in various conditions. Many 
preclinical and clinical studies have revealed higher deposition of Gd in the body 
organs in linear type than those in macrocyclic GBCAs.
Special precaution needs to be taken in cases of chronic kidney disease or 
patients with renal dysfunction as the only route of excretion of the GBCAs is via 
the kidney. Nephrogenic system fibrosis (NSF) has been noted in such renal func-
tion-impaired patients who had been administered GBCAs, especially linear types. 
Moreover, linear GBCAs are easy to release Gd ions from chelates. Linear GBCAs 
have a tendency to be deposited in the human body, including brain tissue. The use 
of macrocyclic GBCAs should be recommended even for patients with normal renal 
function.
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